Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 2件: PML, RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
2 Adherens junction 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
3 Adherens junction 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
4 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
5 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
6 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
7 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
9 Alcoholic liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
10 Alcoholic liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
11 Alcoholic liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
12 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
14 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
15 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
16 AMPK signaling pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
17 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
18 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Antifolate resistance 💬
 1件: TYMS 💬 D01223 💬 Capecitabine 1件: 94 💬
20 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
21 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
22 Arrhythmogenic right ventricular cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
23 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
24 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
25 Bile secretion 💬
 1件: NR1H4 💬 D00734 💬 Ursodeoxycholic acid 14件:  6 ,  8 , 20, 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299 💬
26 Bladder cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
27 Bladder cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
28 Breast cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
29 Breast cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
30 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
31 Calcium signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
32 Calcium signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
33 cAMP signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
34 cAMP signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
35 Cell adhesion molecules 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
36 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
37 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
38 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
39 Chemical carcinogenesis - reactive oxygen species 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
40 Chemical carcinogenesis - reactive oxygen species 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
41 Chemical carcinogenesis - receptor activation 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
42 Chemical carcinogenesis - receptor activation 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
43 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
44 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
45 Chemokine signaling pathway 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
46 Choline metabolism in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
47 Choline metabolism in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
48 Colorectal cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
49 Colorectal cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
50 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
51 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
52 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
53 Cushing syndrome 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
54 Cushing syndrome 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
55 Cytokine-cytokine receptor interaction 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
56 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
57 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
58 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
59 Dilated cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
60 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
61 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
62 Drug metabolism - other enzymes 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
63 ECM-receptor interaction 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
64 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
65 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
66 Endocrine resistance 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
67 Endocrine resistance 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
68 Endocytosis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
69 Endocytosis 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
70 Endocytosis 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
71 Endocytosis 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
72 Endometrial cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
73 Endometrial cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
74 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
75 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
76 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
77 ErbB signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
78 ErbB signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
79 Estrogen signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
80 Estrogen signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
81 Estrogen signaling pathway 💬
 1件: RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
82 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
83 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
84 Focal adhesion 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
85 Focal adhesion 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
86 Focal adhesion 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
87 FoxO signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
88 FoxO signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
89 Gap junction 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
90 Gap junction 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
91 Gastric cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
92 Gastric cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
93 Gastric cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
94 Glioma 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
95 Glioma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
96 Glucagon signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
97 Glucagon signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
98 Glutathione metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
99 GnRH signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
100 GnRH signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
101 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
102 Hematopoietic cell lineage 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
103 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 49件:  6 , 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
104 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
105 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
106 Hepatitis C 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
107 Hepatitis C 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
108 Hepatitis C 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
109 Hepatitis C 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
110 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
111 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
112 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
113 Herpes simplex virus 1 infection 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
114 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
115 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
116 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
117 Human cytomegalovirus infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
118 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
119 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
120 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
121 Human immunodeficiency virus 1 infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
122 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
123 Human papillomavirus infection 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
124 Human papillomavirus infection 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
125 Human papillomavirus infection 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
126 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
127 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
128 Huntington disease 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
129 Hypertrophic cardiomyopathy 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
130 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
131 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
132 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
133 Influenza A 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
134 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
135 Insulin resistance 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
136 Insulin resistance 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
137 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
138 Intestinal immune network for IgA production 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
139 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
140 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
141 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
142 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
143 Leishmaniasis 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
144 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
145 Leukocyte transendothelial migration 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
146 Lipid and atherosclerosis 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
147 Lipid and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
148 Longevity regulating pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
149 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
150 MAPK signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
151 MAPK signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
152 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
153 Melanoma 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
154 Melanoma 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
155 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
156 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
157 Metabolic pathways 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
158 Metabolic pathways 💬
 1件: TYMS 💬 D01223 💬 Capecitabine 1件: 94 💬
159 MicroRNAs in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
160 MicroRNAs in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
161 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
162 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
163 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
164 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00246 💬 Budesonide 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
165 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
166 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
167 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
168 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
169 Non-alcoholic fatty liver disease 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
170 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
171 Non-small cell lung cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
172 Non-small cell lung cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
173 Non-small cell lung cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
174 One carbon pool by folate 💬
 1件: TYMS 💬 D01223 💬 Capecitabine 1件: 94 💬
175 Osteoclast differentiation 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
176 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
177 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
178 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
179 Pancreatic cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
180 Pancreatic cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
181 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
182 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
183 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
184 Pathways in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
185 Pathways in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
186 Pathways in cancer 💬
 3件: PML, RARA, RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
187 Pathways in cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
188 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
189 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
190 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
191 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
192 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
193 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
194 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
195 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
196 PI3K-Akt signaling pathway 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
197 PPAR signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
198 PPAR signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 5件:  8 , 79, 93, 94, 265 💬
199 PPAR signaling pathway 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
200 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
201 Prostate cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
202 Prostate cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
203 Proteoglycans in cancer 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
204 Proteoglycans in cancer 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
205 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
206 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 D01392 💬 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224 💬
207 Purine metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
208 Pyrimidine metabolism 💬
 1件: RRM1 💬 D01370 💬 Cladribine 3件: 11, 13, 94 💬
209 Pyrimidine metabolism 💬
 1件: TYMS 💬 D01223 💬 Capecitabine 1件: 94 💬
210 Rap1 signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
211 Rap1 signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
212 Ras signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
213 Ras signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
214 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
215 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
216 Regulation of actin cytoskeleton 💬
 2件: ITGA4, ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
217 Relaxin signaling pathway 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
218 Relaxin signaling pathway 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
219 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
220 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
221 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
222 Shigellosis 💬
 1件: EGFR 💬 D04023 💬 Erlotinib 1件: 94 💬
223 Shigellosis 💬
 1件: EGFR 💬 D07907 💬 Erlotinib 1件: 94 💬
224 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
225 Small cell lung cancer 💬
 1件: RARB 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
226 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
227 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
228 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
229 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
230 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
231 Th17 cell differentiation 💬
 1件: RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
232 Thermogenesis 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
233 Thyroid cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
234 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
235 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
236 Toxoplasmosis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
237 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
238 Transcriptional misregulation in cancer 💬
 1件: ITGB7 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
239 Transcriptional misregulation in cancer 💬
 2件: PML, RARA 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
240 Transcriptional misregulation in cancer 💬
 1件: PPARG 💬 D11256 💬 Seladelpar 2件: 93, 94 💬
241 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
242 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
243 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
244 Ubiquitin mediated proteolysis 💬
 1件: PML 💬 D00094 💬 Tretinoin 6件:  2 , 62, 63, 75, 94, 231 💬
245 Viral carcinogenesis 💬
 1件: CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
246 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: CCR2, CCR5 💬 D09878 💬 Cenicriviroc 1件: 94 💬
247 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
248 Yersinia infection 💬
 1件: ITGA4 💬 D08083 💬 Vedolizumab 3件: 94, 96, 97 💬
249 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ